Geneuro SA - ESG Rating & Company Profile powered by AI
The report of Geneuro SA incorporates data from across the internet as well as from public documents by Geneuro SA. The Disclosure rating includes seventeen UN SDGs including: 'Gender Equality', 'Industry, Innovation & Infrastructure' and 'Peace, Justice & Strong Institutions'. This webpage of Geneuro SA was prepared by All Street Sevva using proprietary Cognitive Robots.
Geneuro SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.3; made up of an environmental score of 4.0, social score of 8.0 and governance score of 6.9.
6.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 535 | aTyr Pharma Inc | 6.4 | High |
| 535 | Verastem Inc | 6.4 | High |
| 563 | Geneuro SA | 6.3 | High |
| 563 | Acasti Pharma Inc | 6.3 | High |
| 563 | Adamas Pharmaceuticals Inc | 6.3 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Geneuro SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Geneuro SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Geneuro SA report the average age of the workforce?
Sign up for free to unlockDoes Geneuro SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Geneuro SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Geneuro SA disclose cybersecurity risks?
Sign up for free to unlockDoes Geneuro SA offer flexible work?
Sign up for free to unlockDoes Geneuro SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Geneuro SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Geneuro SA conduct supply chain audits?
Sign up for free to unlockDoes Geneuro SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Geneuro SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Geneuro SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Geneuro SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Geneuro SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Geneuro SA disclose water use targets?
Sign up for free to unlockDoes Geneuro SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Geneuro SA have a product recall in the last two years?
Sign up for free to unlockDoes Geneuro SA disclose incidents of discrimination?
Sign up for free to unlockDoes Geneuro SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Geneuro SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Geneuro SA disclose parental leave metrics?
Sign up for free to unlockDoes Geneuro SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Geneuro SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Geneuro SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Geneuro SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Geneuro SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Geneuro SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Geneuro SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Geneuro SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Geneuro SA disclose its waste policy?
Sign up for free to unlockDoes Geneuro SA report according to TCFD requirements?
Sign up for free to unlockDoes Geneuro SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Geneuro SA disclose energy use targets?
Sign up for free to unlockDoes Geneuro SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Geneuro SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Geneuro SA
These potential risks are based on the size, segment and geographies of the company.
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.